Clinical Trials

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT03386357 2026-03-12

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Terminated

115 enrolled 15 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07465276 2026-03-11

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT07455032 2026-03-06

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

22 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05977907 2026-03-03

KIEO

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07343596 2026-03-03

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

Phase NA Recruiting

Mouth Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

214 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

30 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Thyroid Neoplasms

NCT03480672 2026-02-17

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

211 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06557889 2026-02-11

REDUCE

86 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05232851 2026-02-10

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1/2 Completed

Carcinoma, Oropharyngeal Neoplasms

NCT05286060 2026-02-09

GENUINE

56 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05980000 2026-02-06

Rambro2

37 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04754321 2026-02-02

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

45 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

45 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT04266730 2026-01-28

PANDA-VAC

6 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT04858269 2026-01-28

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

36 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Terminated

14 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02819752 2026-01-21

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06236425 2026-01-08

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

7 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03942653 2025-12-31

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Salivary Gland Neoplasms

NCT04227509 2025-12-31

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

53 enrolled

Phase 1/2 Active not recruiting

Nasopharyngeal Carcinoma

NCT03650764 2025-12-30

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

43 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05119296 2025-12-22

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

12 enrolled

Thyroid Neoplasms

NCT05420948 2025-12-22

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

30 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04414540 2025-12-19

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07264075 2025-12-04

ILLUMINE

Phase 3 Not yet recruiting

780 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

DermatologicHead & NeckSarcoma

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

36 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT04454489 2025-11-19

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

21 enrolled 18 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

51 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04323202 2025-10-24

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Phase 1 Completed

13 enrolled

DermatologicHead & Neck

Basal Cell Carcinoma of the Head and Neck

NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

15 enrolled 8 charts